Clinical Implication of Highly Sensitive Detection of the BRAFV600E Mutation in Fine-Needle Aspirations According to the Thyroid Bethesda System in Patients With Conventional Papillary Thyroid Carcinoma

被引:12
|
作者
Seo, Jae Young [1 ,2 ,3 ]
Choi, Jong Rak [4 ]
Moon, Hee Jung [1 ,2 ]
Kim, Eun-Kyung [1 ,2 ]
Han, Kyung Hwa [5 ]
Kim, Hyunki [6 ,7 ]
Kwak, Jin Young [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Radiol, Seoul 120749, South Korea
[2] Yonsei Univ, Coll Med, Severance Hosp, Res Inst Radiol Sci, Seoul 120749, South Korea
[3] Konyang Univ, Coll Med, Konyang Univ Hosp, Dept Radiol, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Severance Hosp, Dept Lab Med, Seoul 120749, South Korea
[5] Yonsei Univ, Coll Med, Med Res Ctr, Biostat Collaborat Unit, Seoul 120749, South Korea
[6] Yonsei Univ, Coll Med, Severance Hosp, Dept Pathol, Seoul 120749, South Korea
[7] Yonsei Univ, Coll Med, Severance Hosp, Res Inst Radiol Sci, Seoul 120749, South Korea
来源
基金
新加坡国家研究基金会;
关键词
proto-oncogene proteins BRAF; mutation; thyroid cancer; papillary; biopsy; fine-needle; cytology; DIAGNOSTIC-ACCURACY; PREVALENT AREA; NODULES; BIOPSY; BRAF; ULTRASOUND; SAMPLES; IMPROVES; PCR;
D O I
10.1177/0003489414560433
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: We investigated the additional diagnostic yield of the mutation test and evaluated the frequency of the BRAF mutation in conventional PTC (cPTC) according to ultrasound (US) features and the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) based on the BRAF(V600E) mutation status. Materials and Methods: During the study period, 279 patients who underwent FNA with an additional BRAF(V600E) mutation test were diagnosed as cPTC after surgery. We analyzed the association between the mutation and several clinical factors. Results: Of the 279 cPTCs, 250 (89.6%) had the BRAF(V600E) mutation. The BRAF mutation test was helpful in diagnosing an additional 19% (53/279) of cPTCs. The frequency of the BRAF mutation in cPTCs with suspicious US features was higher than that of cPTCs with negative US features regardless of the BSRTC. Conclusions: Suspicious US features may be helpful in deciding whether an additional BRAF(V600E) mutation test should be done in thyroid nodules with indeterminate cytology.
引用
收藏
页码:392 / 399
页数:8
相关论文
共 50 条
  • [41] The Role Of BRAFV600E Mutation In Predicting Clinical Response Of Radioiodine Therapy In Papillary Thyroid Carcinoma
    Shen, G.
    Kuang, A.
    Huang, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S607 - S607
  • [42] BRAFV600E genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration
    Lu, Yiran
    Guo, Xinghong
    Yang, Mengmeng
    Wang, Kewei
    Cao, Guanglei
    Liu, Yan
    Hou, Xinguo
    Chen, Li
    Liang, Kai
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [43] BRAFV600E genetic testing should be recommended for Bethesda III or V thyroid nodules based on fine-needle aspiration
    Yiran Lu
    Xinghong Guo
    Mengmeng Yang
    Kewei Wang
    Guanglei Cao
    Yan Liu
    Xinguo Hou
    Li Chen
    Kai Liang
    Scientific Reports, 13
  • [44] Clinical significance of BRAFV600E and TERT promoter mutation in papillary thyroid microcarcinoma
    Jincai Xue
    Qinjiang Liu
    Youxin Tian
    Xiaofeng Hou
    OncologyandTranslationalMedicine, 2019, 5 (02) : 75 - 79
  • [45] Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status
    Karakose, Melia
    Caliskan, Mustafa
    Arslan, Muyesser Sayki
    Cakal, Erman
    Yesilyurt, Ahmet
    Delibasi, Tuncay
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2015, 59 (04): : 364 - 366
  • [46] BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma
    Ahn, Dongbin
    Park, June Sik
    Sohn, Jin Ho
    Kim, Jae Hyug
    Park, Sun-Kyun
    Seo, An Na
    Park, Ji Young
    AURIS NASUS LARYNX, 2012, 39 (02) : 198 - 203
  • [47] Clinical significance of preoperative detection of serum p53 antibodies and BRAFV600E mutation in patients with papillary thyroid carcinoma
    Fu, Qing-Feng
    Pan, Peng-Tao
    Zhou, Le
    Liu, Xiao-Li
    Guo, Feng
    Wang, Li
    Sun, Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (11): : 21327 - 21334
  • [48] Clinical and Pathological Features and the BRAFV600E Mutation in Patients with Papillary Thyroid Carcinoma with and without Concurrent Hashimoto Thyroiditis
    Kim, Suk Kyeong
    Song, Kee-Ho
    Lim, So Duk
    Lim, Young Chang
    Yoo, Young Bum
    Kim, Ji Soo
    Hwang, Tae Sook
    THYROID, 2009, 19 (02) : 137 - 141
  • [49] Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
    Kim, Kevin B.
    Cabanillas, Maria E.
    Lazar, Alexander J.
    Williams, Michelle D.
    Sanders, Deborah L.
    Ilagan, Joseph L.
    Nolop, Keith
    Lee, Richard J.
    Sherman, Steven I.
    THYROID, 2013, 23 (10) : 1277 - 1283
  • [50] BRAFV600E mutation analysis in fnab specimen of thyroid nodules as an adjunct to conventional fine needle aspiration cytology
    Kim, S.
    Han, H.
    Lim, S.
    Kim, W.
    Oh, S.
    Hwang, T.
    HISTOPATHOLOGY, 2008, 53 : 104 - 104